Is ESTA or SIBN more profitable?

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -19.05% -218.77% -12.31% SiBone -8.10% -9.56% -7.06%

Which has stronger earnings & valuation, SIBN or AXGN?

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.90 -$18.90M -$0.39 N/A AxoGen $225.21M 10.86 -$15.70M -$0.64 N/A

Is SIBN or AXGN more profitable?

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% AxoGen -13.21% -9.63% -6.26%

Which has preferable earnings & valuation, TMDX or SIBN?

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.07 $190.29M $4.40 16.19 SiBone $200.93M 3.90 -$18.90M -$0.39 N/A

Which has preferable valuation and earnings, LMAT or SIBN?

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 9.50 $57.73M $2.71 38.27 SiBone $200.93M 3.90 -$18.90M -$0.39 N/A

Which has preferable earnings and valuation, SIBN or BFLY?

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.90 -$18.90M -$0.39 N/A Butterfly Network $97.61M 21.42 -$77.06M -$0.30 N/A

SiBone (SIBN) Competitors

$17.68 +0.57 (+3.33%)

Closing price 07/6/2026 04:00 PM Eastern

Extended Trading

$17.70 +0.02 (+0.12%)

As of 06:06 AM Eastern

Compare

SIBN vs. ESTA, AXGN, TMDX, LMAT, and BFLY

Should you buy SiBone stock or one of its competitors? MarketBeat compares SiBone with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SiBone include Establishment Labs (ESTA), AxoGen (AXGN), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.

How does SiBone compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Establishment Labs has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Establishment Labs presently has a consensus price target of $87.14, suggesting a potential downside of 4.82%. SiBone has a consensus price target of $23.00, suggesting a potential upside of 30.09%. Given SiBone's stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
SiBone	-8.10%	-9.56%	-7.06%

SiBone has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.77	-$51.06M	-$1.49	N/A
SiBone	$200.93M	3.90	-$18.90M	-$0.39	N/A

In the previous week, Establishment Labs had 1 more articles in the media than SiBone. MarketBeat recorded 3 mentions for Establishment Labs and 2 mentions for SiBone. Establishment Labs' average media sentiment score of 0.88 beat SiBone's score of 0.00 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Establishment Labs	Positive
SiBone	Neutral

Summary

SiBone beats Establishment Labs on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to AxoGen?

SiBone (NASDAQ:SIBN) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
AxoGen	-13.21%	-9.63%	-6.26%

SiBone has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

In the previous week, AxoGen had 3 more articles in the media than SiBone. MarketBeat recorded 5 mentions for AxoGen and 2 mentions for SiBone. AxoGen's average media sentiment score of 1.37 beat SiBone's score of 0.00 indicating that AxoGen is being referred to more favorably in the news media.

Company	Overall Sentiment
SiBone	Neutral
AxoGen	Positive

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.90	-$18.90M	-$0.39	N/A
AxoGen	$225.21M	10.86	-$15.70M	-$0.64	N/A

SiBone presently has a consensus target price of $23.00, indicating a potential upside of 30.09%. AxoGen has a consensus target price of $46.50, indicating a potential upside of 1.15%. Given SiBone's higher probable upside, equities analysts clearly believe SiBone is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

98.1% of SiBone shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 3.9% of SiBone shares are owned by insiders. Comparatively, 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

AxoGen beats SiBone on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.07	$190.29M	$4.40	16.19
SiBone	$200.93M	3.90	-$18.90M	-$0.39	N/A

TransMedics Group has a net margin of 27.04% compared to SiBone's net margin of -8.10%. TransMedics Group's return on equity of 22.38% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
SiBone	-8.10%	-9.56%	-7.06%

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 3.9% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, TransMedics Group had 5 more articles in the media than SiBone. MarketBeat recorded 7 mentions for TransMedics Group and 2 mentions for SiBone. TransMedics Group's average media sentiment score of 0.15 beat SiBone's score of 0.00 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Overall Sentiment
TransMedics Group	Neutral
SiBone	Neutral

TransMedics Group presently has a consensus target price of $134.50, indicating a potential upside of 88.82%. SiBone has a consensus target price of $23.00, indicating a potential upside of 30.09%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

TransMedics Group has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Summary

TransMedics Group beats SiBone on 14 of the 15 factors compared between the two stocks.

How does SiBone compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

LeMaitre Vascular has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, SiBone has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.50	$57.73M	$2.71	38.27
SiBone	$200.93M	3.90	-$18.90M	-$0.39	N/A

LeMaitre Vascular has a net margin of 24.35% compared to SiBone's net margin of -8.10%. LeMaitre Vascular's return on equity of 15.36% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
SiBone	-8.10%	-9.56%	-7.06%

LeMaitre Vascular presently has a consensus price target of $112.60, indicating a potential upside of 8.56%. SiBone has a consensus price target of $23.00, indicating a potential upside of 30.09%. Given SiBone's higher possible upside, analysts plainly believe SiBone is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, LeMaitre Vascular had 2 more articles in the media than SiBone. MarketBeat recorded 4 mentions for LeMaitre Vascular and 2 mentions for SiBone. LeMaitre Vascular's average media sentiment score of 1.51 beat SiBone's score of 0.00 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Overall Sentiment
LeMaitre Vascular	Very Positive
SiBone	Neutral

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 3.9% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

LeMaitre Vascular beats SiBone on 13 of the 17 factors compared between the two stocks.

How does SiBone compare to Butterfly Network?

SiBone (NASDAQ:SIBN) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Butterfly Network had 2 more articles in the media than SiBone. MarketBeat recorded 4 mentions for Butterfly Network and 2 mentions for SiBone. Butterfly Network's average media sentiment score of 0.43 beat SiBone's score of 0.00 indicating that Butterfly Network is being referred to more favorably in the news media.

Company	Overall Sentiment
SiBone	Neutral
Butterfly Network	Neutral

98.1% of SiBone shares are owned by institutional investors. Comparatively, 37.9% of Butterfly Network shares are owned by institutional investors. 3.9% of SiBone shares are owned by insiders. Comparatively, 22.0% of Butterfly Network shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

SiBone has higher revenue and earnings than Butterfly Network. SiBone is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.90	-$18.90M	-$0.39	N/A
Butterfly Network	$97.61M	21.42	-$77.06M	-$0.30	N/A

SiBone has a net margin of -8.10% compared to Butterfly Network's net margin of -73.63%. SiBone's return on equity of -9.56% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Butterfly Network	-73.63%	-34.41%	-23.91%

SiBone presently has a consensus price target of $23.00, indicating a potential upside of 30.09%. Butterfly Network has a consensus price target of $5.56, indicating a potential downside of 32.27%. Given SiBone's stronger consensus rating and higher possible upside, analysts clearly believe SiBone is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

SiBone beats Butterfly Network on 9 of the 16 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$758.82M	$7.57B	$6.92B	$12.59B
Dividend Yield	N/A	1.31%	2.66%	6.52%
P/E Ratio	-45.33	52.83	27.35	24.81
Price / Sales	3.90	96.71	507.73	89.92
Price / Cash	N/A	27.33	29.65	49.23
Price / Book	4.32	7.55	11.06	6.50
Net Income	-$18.90M	$159.19M	$3.57B	$336.03M
7 Day Performance	8.33%	1.22%	2.56%	2.68%
1 Month Performance	16.93%	0.84%	7.39%	5.50%
1 Year Performance	-1.83%	4.59%	34.13%	25.01%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	1.9583 of 5 stars	$17.68 +3.3%	$23.00 +30.1%	-4.2%	$758.82M	$200.93M	N/A	350
ESTA Establishment Labs	1.3966 of 5 stars	$86.20 -1.4%	$87.14 +1.1%	+108.6%	$2.54B	$229.58M	N/A	1,004
AXGN AxoGen	2.1794 of 5 stars	$45.11 +0.9%	$46.50 +3.1%	+321.0%	$2.40B	$225.21M	N/A	450	Positive News Analyst Upgrade
TMDX TransMedics Group	4.3091 of 5 stars	$66.45 -1.3%	$134.50 +102.4%	-44.7%	$2.30B	$635.89M	15.10	210
LMAT LeMaitre Vascular	4.2009 of 5 stars	$95.97 0.0%	$112.60 +17.3%	+22.9%	$2.19B	$249.60M	35.35	490	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. ESTA, AXGN, TMDX, LMAT, and BFLY

How does SiBone compare to Establishment Labs?

Summary

How does SiBone compare to AxoGen?

Summary

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to LeMaitre Vascular?

Summary

How does SiBone compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. ESTA, AXGN, TMDX, LMAT, and BFLY

How does SiBone compare to Establishment Labs?

Do institutionals & insiders hold more shares of ESTA or SIBN?

Which has more risk and volatility, ESTA or SIBN?

Do analysts recommend ESTA or SIBN?

Is ESTA or SIBN more profitable?

Which has stronger valuation and earnings, ESTA or SIBN?

Does the media refer more to ESTA or SIBN?

Summary

How does SiBone compare to AxoGen?

Is SIBN or AXGN more profitable?

Which has more risk & volatility, SIBN or AXGN?

Does the media favor SIBN or AXGN?

Which has stronger earnings & valuation, SIBN or AXGN?

Do analysts recommend SIBN or AXGN?

Do institutionals and insiders have more ownership in SIBN or AXGN?

Summary

How does SiBone compare to TransMedics Group?

Which has preferable earnings & valuation, TMDX or SIBN?

Is TMDX or SIBN more profitable?

Do institutionals & insiders believe in TMDX or SIBN?

Does the media prefer TMDX or SIBN?

Do analysts recommend TMDX or SIBN?

Which has more risk and volatility, TMDX or SIBN?

Summary

How does SiBone compare to LeMaitre Vascular?

Which has more volatility & risk, LMAT or SIBN?

Which has preferable valuation and earnings, LMAT or SIBN?

Is LMAT or SIBN more profitable?

Do analysts rate LMAT or SIBN?

Does the media refer more to LMAT or SIBN?

Do institutionals and insiders believe in LMAT or SIBN?

Summary

How does SiBone compare to Butterfly Network?

Does the media favor SIBN or BFLY?

Do insiders & institutionals have more ownership in SIBN or BFLY?

Which has more risk & volatility, SIBN or BFLY?

Which has preferable earnings and valuation, SIBN or BFLY?

Is SIBN or BFLY more profitable?

Do analysts rate SIBN or BFLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools